RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Hyperactivated AKT/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs). Drugs targeting this pathway are used clinically, but tumor resistance invariably develops. A better understanding of factors regulating AKT/mTOR signaling and PNET pathogenesis is needed to improve current...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Umesalma, Shaikamjad, Kaemmer, Courtney A., Kohlmeyer, Jordan L., Letney, Blake, Schab, Angela M., Reilly, Jacqueline A., Sheehy, Ryan M., Hagen, Jussara, Tiwari, Nitija, Zhan, Fenghuang, Leidinger, Mariah R., O’Dorisio, Thomas M., Dillon, Joseph, Merrill, Ronald A., Meyerholz, David K., Perl, Abbey L., Brown, Bart J., Braun, Terry A., Scott, Aaron T., Ginader, Timothy, Taghiyev, Agshin F., Zamba, Gideon K., Howe, James R., Strack, Stefan, Bellizzi, Andrew M., Narla, Goutham, Darbro, Benjamin W., Quelle, Frederick W., Quelle, Dawn E.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436899/
https://ncbi.nlm.nih.gov/pubmed/30721156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123049
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items